Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.

Histological and Immunological Evaluation of Gastrointestinal Stromal Tumors

Background: Gastrointestinal stromal tumors (GISTs) constitute the majority of gastrointestinal mesenchymal tumors. They usually express a proto-oncogen protein called CD117 detected by immunohistochemistry. This study investigated the differentiation of GISTs as well as the risk of aggressive behaviors in GISTs from surgically-treated patients in university affiliated hospitals. Methods: The c...

The study of 13 cases of Gastrointestinal stromal tumors in Kerman

13 cases of  gastrointestinal stromal tumors (GIST) diagnosed in Kerman university hospitals between 1370-1376 are reviewed.of these cases,6 were male and 7 were female.patients, age ranged between 19 to 70 years with a median of 47.8 years. in 8 cases tumor developed in stomach and in 5 cases it originated from small intestine.all available H & E stained slides were reviewed and PAS and masson...

Granulosa Cell – Stromal Tumors: An Immunohistochemical Study Including Comparison of Calretinin and Inhibin

Background and Objective: Histopathological evaluation of granulosa cell tumors (GCT) of the ovary may be confused morphologically with a wide variety of the tumors. Immunohistochemical staining for inhibin and calretinin can be used for better diagnosis. Although it has been suggested that inhibin can be a sensitive marker for GCT, it maybe had negative results in some cases.  In addition, cal...

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.

The potential value of F-18 FDG PET in comparison to ct in early prediction of response to Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors

  Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GIST has been shown to over-express c-KIT (CD117), the receptor tyrosine kinase. Imatinib (STI571 or Glivec) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases and has been successfully used to trea...